Home Featured Page 161

Featured

Latest

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

Inflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

EDITOR PICKS

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

Inflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

EDITOR PICKS

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY